Free Trial

Celadon Pharmaceuticals (CEL) Competitors

Celadon Pharmaceuticals logo
GBX 6.40 -0.10 (-1.54%)
As of 04/17/2025 09:49 AM Eastern

CEL vs. CNSL, OTT, BCE, FOX, CZN, CHT, DVW, BRCI, NPT, and RCI

Should you be buying Celadon Pharmaceuticals stock or one of its competitors? The main competitors of Celadon Pharmaceuticals include Cambridge Nutritional Sciences (CNSL), Oxford Technology 3 Venture Capital Trust (OTT), Beacon Energy (BCE), Fox Marble (FOX), Curzon Energy (CZN), 290005 (CHT.L) (CHT), 5008 (DVW.L) (DVW), BlackRock Comms Income Inv Tst (BRCI), NetPlay TV (NPT), and RapidCloud International (RCI). These companies are all part of the "communication" industry.

Celadon Pharmaceuticals vs.

Celadon Pharmaceuticals (LON:CEL) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends.

In the previous week, Celadon Pharmaceuticals' average media sentiment score of 0.00 equaled Cambridge Nutritional Sciences'average media sentiment score.

Company Overall Sentiment
Celadon Pharmaceuticals Neutral
Cambridge Nutritional Sciences Neutral

10.7% of Celadon Pharmaceuticals shares are held by institutional investors. Comparatively, 10.2% of Cambridge Nutritional Sciences shares are held by institutional investors. 65.1% of Celadon Pharmaceuticals shares are held by insiders. Comparatively, 10.9% of Cambridge Nutritional Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Celadon Pharmaceuticals has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Comparatively, Cambridge Nutritional Sciences has a beta of 3.89, suggesting that its stock price is 289% more volatile than the S&P 500.

Celadon Pharmaceuticals received 4 more outperform votes than Cambridge Nutritional Sciences when rated by MarketBeat users.

CompanyUnderperformOutperform
Celadon PharmaceuticalsOutperform Votes
4
100.00%
Underperform Votes
No Votes
Cambridge Nutritional SciencesN/AN/A

Cambridge Nutritional Sciences has higher revenue and earnings than Celadon Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celadon Pharmaceuticals£123.38K31.81-£4.97M-£7.98-0.80
Cambridge Nutritional Sciences£9.77M0.62-£3.03MN/AN/A

Cambridge Nutritional Sciences has a net margin of -3.36% compared to Celadon Pharmaceuticals' net margin of -4,024.62%. Cambridge Nutritional Sciences' return on equity of -3.34% beat Celadon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Celadon Pharmaceuticals-4,024.62% -187.26% -34.40%
Cambridge Nutritional Sciences -3.36%-3.34%-2.36%

Summary

Cambridge Nutritional Sciences beats Celadon Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Celadon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CEL and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CEL vs. The Competition

MetricCeladon PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£3.93M£2.13B£5.30B£2.50B
Dividend YieldN/A2.92%5.45%4.79%
P/E Ratio-0.804.3321.86130.25
Price / Sales31.81478.32380.66234,001.07
Price / Cash3.0510.2538.2628.23
Price / Book1.696.146.454.41
Net Income-£4.97M£20.70B£3.22B£5.87B
1 Month Performance-53.62%-3.01%-9.76%-1.38%
1 Year Performance-94.67%93.89%11.49%41.26%

Celadon Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CEL
Celadon Pharmaceuticals
N/AGBX 6.40
-1.5%
N/A-94.5%£3.93M£123,381.65-0.802,780Positive News
Gap Up
CNSL
Cambridge Nutritional Sciences
N/AGBX 2.55
-3.8%
N/A-20.6%£6.07M£9.77M-362.103,200Gap Down
OTT
Oxford Technology 3 Venture Capital Trust
N/AN/AN/AN/A£2.13M£-85,000.00-12.59203Gap Down
BCE
Beacon Energy
N/AGBX 0
flat
N/A-94.0%£555,000.00N/A-0.3544,600
FOX
Fox Marble
N/AGBX 0.04
-4.7%
N/A-97.0%£171,000.00£722,064.00-135.0010,600Gap Down
CZN
Curzon Energy
N/AN/AN/AN/A£34,000.00N/A-3.4014,700Gap Down
CHT
290005 (CHT.L)
N/AN/AN/AN/A£0.00N/A0.0020,300
DVW
5008 (DVW.L)
N/AN/AN/AN/A£0.00N/A0.00N/AGap Up
BRCI
BlackRock Comms Income Inv Tst
N/AN/AN/AN/A£0.00N/A0.00N/AHigh Trading Volume
NPT
NetPlay TV
N/AN/AN/AN/A£0.00N/A0.00147,000
RCI
RapidCloud International
N/AN/AN/AN/A£0.00N/A0.0023,000

Related Companies and Tools


This page (LON:CEL) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners